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feeBACKGROUND Prolonged dual antiplatelet therapy (DAPT) is recommended after an acute myocardial infarction (AMI)
to reduce ischemic events but is associated with increased rates of major and minor bleeding.
OBJECTIVES This study sought to determine the incidence of post-percutaneous coronary intervention (PCI) bleeding
that occurs on contemporary DAPT and its impact on quality of life (QOL).
METHODS We studied 9,290 AMI patients treated with PCI and discharged alive between April 2010 and September
2012. Post-discharge bleeding was categorized according to the Bleeding Academic Research Consortium (BARC) deﬁ-
nition. The primary outcome was the 6-month Euro QOL–5 Dimension (EQ-5D) index score (a measure of health utility); a
secondary outcome was the EQ-5D visual analog scale (VAS) at 6 months.
RESULTS Of the 9,290 patients with AMI, bleeding events occurred as follows: any BARC bleeding: 24.2%; BARC 1:
9.1%; BARC 2: 13.8%; BARC 3: 1.1%; BARC 4: 0.03%; and BARC 5: 0%. Those who experienced any BARC bleeding had
lower scores across all 5 EQ-5D domains (mobility, self-care, usual activities, pain, and anxiety), as well as lower EQ-5D
VAS and EQ-5D index scores. After clinical risk adjustment, any BARC bleeding was independently associated with
6-month EQ-5D index score (p < 0.0001) and lower QOL (p < 0.001). Both the EQ-5D index and the VAS score declined
in a stepwise fashion with increasing BARC severity.
CONCLUSIONS Among patients undergoing PCI for AMI, bleeding during follow-up was associated with worse
6-month utility and QOL. Although even minor bleeding was associated with impaired health status and QOL, the degree
of impairment increased in a stepwise fashion with bleeding severity. (J Am Coll Cardiol 2016;67:59–65)
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AMI = acute myocardial
infarction
BARC = Bleeding Academic
Research Consortium
DAPT = dual antiplatelet
therapy
DCRI = Duke Clinical Research
Institute
EQ-5D = Euro QOL–5
Dimension
PCI = percutaneous coronary
intervention
QOL = quality of life
STEMI = ST-segment elevation
myocardial infarction
VAS = visual analog scale
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60T he incidence and prognostic signiﬁ-cance of bleeding occurring duringhospitalization for an acute myocar-
dial infarction (AMI) or following percuta-
neous coronary intervention (PCI) is well
recognized (1–5). However, little is known
about the risk of post-discharge bleeding in
patients on dual antiplatelet therapy (DAPT)
after AMI or PCI. The prognostic signiﬁcance
of post-discharge bleeding of patients on
DAPT was recently underscored using the
Bleeding Academic Research Consortium
(BARC) consensus deﬁnitions, which were
developed to standardize the reporting of
bleeding in clinical trials and practice. Several
studies and trials have now validated these
deﬁnitions (6–10) and their value in outpa-
tient assessment of bleeding via a telephone
interview. It is now possible to identify veryminor BARC type 1 bleeding, deﬁned as “bleeding
that does not cause the patient to seek medical care
or hospitalization, and is not actionable” but may still
be signiﬁcant from the patient’s perspective (8).SEE PAGE 66The incidence and impact of post-PCI bleeding on
patient quality of life (QOL) after AMI have not been
well studied, particularly in the context of a greater
uptake of the more potent P2Y12 inhibitors in routine
contemporary practice. Additionally, the health-state
“disutility” of bleeding events according to increasing
severity of the BARC bleeding deﬁnition has never
been quantiﬁed. Therefore, we examined data from
the large prospective, multicenter TRANSLATE-ACS
(Treatment With Adenosine Diphosphate [ADP] Re-
ceptor Inhibitors: Longitudinal Assessment of Treat-
ment Patterns and Events After Acute Coronary
Syndrome) study (NCT01088503) study (11) that
collected both patient self-reported and hospitalized
bleeding events to: 1) investigate the incidence of
bleeding after PCI for an AMI; and 2) examine the
impact of bleeding events on health-related QOL and
health-state utilities.
METHODS
The TRANSLATE-ACS study is a prospective obser-
vational longitudinal registry led by the Duke Clinical
Research Institute (DCRI) and conducted at 233eneca. All other authors have reported that they have no relationsh
l, MD, served as Guest Editor for this paper.
received September 14, 2015; accepted October 4, 2015.hospitals in the United States from April 2010 to
October 2012 (11). The TRANSLATE-ACS study
enrolled 12,365 patients with either ST-segment
elevation myocardial infarction (STEMI) or non-
STEMI who underwent PCI and were treated with an
ADP receptor inhibitor during the index hospitaliza-
tion. Patients were excluded from the TRANSLATE-
ACS study if informed consent for longitudinal
follow-up could not be obtained or if the patient was
participating in a clinical trial specifying ADP receptor
inhibitor use during the ﬁrst year post-AMI.
For this analysis, we started with 11,649 patients
and excluded those who died in hospital (n ¼ 13) or by
6 months (n ¼ 106), those with missing baseline
(n ¼ 76) or 6-month Euro QOL–5 Dimension (EQ-5D)
data (n ¼ 1,928), and those with incomplete medical
records or whose hospitalization events could not be
validated (n ¼ 236), resulting in a ﬁnal population of
9,290 subjects.
DATA DEFINITIONS. Patient-reported bleeding was
assessed via centralized telephone interviews con-
ducted by the DCRI at 6 weeks and 6 months
post-AMI. Post-discharge bleeding was deﬁned as
any bleeding or severe bruising event that was
patient-reported, associated with an antiplatelet
medication change, or an independently adjudicated
bleeding rehospitalization based on medical record
review. Each bleeding event was classiﬁed according
to the BARC deﬁnitions (8). BARC type 1 bleeding
represented bleeding that was not actionable and did
not cause the patient to seek unscheduled studies or
treatment and was ascertained by patient report.
BARC type 2 reﬂected overt actionable bleeding not
ﬁtting criteria for the other bleeding types. For pa-
tients with multiple bleeding events, the most severe
BARC bleeding type was assigned (12).
The EQ-5D index score collected at the 6-month pa-
tient interview was the primary outcome of interest.
This score is an indirect measure of utility for health,
measuring health status in 5 dimensions: mobility, self-
care, usual activities, pain/discomfort, and anxiety/
depression. It generates an index-based summary score
based upon societal preference weights (13–15) using a
unique scoring algorithm (13). Utility scores enable
comparisons of burden of disease across conditions and
the calculation of quality-adjusted life-years, an
outcome used frequently to evaluate the cost-effec-
tiveness of health care programs and strategies. Weips relevant to the contents of this paper to disclose.
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61calculated the EQ-5D index score from the EQ-5D do-
mains both at baseline and at 6months. Of note, the EQ-
5D has previously been validated for ACS patients (14).
Six-month health-related QOL assessed via the
EQ-5D visual analog scale (VAS) score was the sec-
ondary outcome of interest. For this endpoint, pa-
tients estimate their overall health status on a 20-cm
VAS with the endpoints being “Best imaginable
health state” (score ¼ 100) and “Worst imaginable
health state” (score ¼ 0) (14,15).
STATISTICAL ANALYSIS. Baseline patient demo-
graphic and clinical characteristics were compared by
post-discharge BARC bleeding status (any BARC
bleeding vs. none) using the chi-square test for
categorical variables and the Wilcoxon rank sum
test for continuous variables. To estimate the inde-
pendent association between post-discharge BARC
bleeding and 6-month EQ-5D index, we developed a
mixed-effects linear regression model with 6-month
EQ-5D index as the dependent variable, adjusting for
baseline EQ-5D index as a covariate and with site as
random effect (16) (hierarchical model). The model
adjusted for other demographic and disease severity
characteristics, as well as potential confounders of the
relationship between bleeding and health status: age,
sex, race, insurance status, body mass index, diabetes,
hypertension, smoking, prior PCI, prior MI, prior cor-
onary artery bypass graft surgery, peripheral vascular
disease, stroke, dialysis, lung disease, congestive heart
failure within the prior 2 weeks, cardiogenic shock
within 24 h, atrial ﬁbrillation, multivessel disease,
ejection fraction, MI type (STEMI vs. non-STEMI),
heart rate, blood pressure, baseline laboratory values
of creatinine and hemoglobin, second-generation ADP
receptor inhibitor use at discharge, warfarin or other
anticoagulant agent use at discharge, Patient Health
Questionnaire-2 depression score, marital status, and
employment status. A similar approach was used to
analyze the secondary outcome of EQ-5D VAS.
In order to place these results into a clinical
context, we also estimated the magnitude of the dif-
ference in QOL by using Cohen’s d, which is a
dimensionless index that measures the magnitude of
a treatment effect (17,18). Cohen’s d is the standard-
ized difference between 2 means and is given by:
q ¼ m1  m2
s
where m1 is the mean for one population, m2 is
the mean for the other population, and s is the
population SD (17,18). An effect size of 0.2 is consid-
ered small, 0.5 moderate, and 0.8 large (18).
Finally, we compared the disutility of minor bleeding(BARC type 1) with more severe bleeding (BARC types
2 to 5 or BARC types 3 to 5) using the same modeling
approach detailed in the preceding text. All analyses
were conducted using SAS version 9.2 (SAS Institute,
Cary, North Carolina) by an independent statistician
at the DCRI.
RESULTS
Among the 9,290 AMI patients in the TRANSLATE-
ACS study who underwent PCI and were discharged
on DAPT, 51% presented with STEMI, 10% underwent
PCI via radial access, 10% underwent multivessel PCI,
and drug-eluting stents were used in 72%. In-hospital
major bleeding occurred in 3%, and DAPT at discharge
included clopidogrel in 68%, prasugrel in 29%, and
ticagrelor in 2%.
INCIDENCE OF BLEEDING DURING FOLLOW-UP.
Over the 6-month follow-up period, any BARC
bleeding occurred in 2,246 (24.2%) of the 9,290 AMI
patients. BARC type I bleeding occurred in 849 (9.1%)
patients. The incidence of more severe bleeding was
as follows: BARC type 2 (13.8%), BARC type 3a (0.5%),
BARC type 3b (0.6%), and BARC type 4 (0.03%). There
were no patients with fatal (BARC type 5) bleeding.
According to the clinical characteristics of patients
with any BARC bleeding versus those who did not
bleed (Table 1), patients with any BARC bleeding
post-discharge were more likely to be female, have a
lower body weight, have a slightly lower hemoglobin
and creatinine clearance, and less likely to be of black
race or have diabetes or a prior PCI. They were also
more likely to experience an overt bleeding episode
during their index ACS hospitalization. Patients with
post-discharge bleeding were more likely to have
been discharged on a higher-potency ADP receptor
inhibitor such as prasugrel or ticagrelor and were
more likely to have been receiving an oral anticoag-
ulant agent at discharge (Table 1).
ASSOCIATION OF BARC BLEEDING WITH HEALTH-
STATE UTILITY AND QOL. Patients who developed
any BARC bleeding had lower baseline responses
across the EQ-5D domains of mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression
compared with those without subsequent bleeding
(Online Table 1, Online Figure 1). The baseline EQ-5D
index health-state utility scores were 0.83  0.19
versus 0.86  0.17 (mean difference 0.03; p < 0.0001)
for patients with bleeding versus no bleeding. At
6-month follow-up, these values were 0.82  0.19
versus 0.86  0.17 (mean difference 0.04; p < 0.0001).
Similarly, baseline EQ-5D VAS scores were also
lower for patients with bleeding versus no bleeding
TABLE 1 Baseline Demographics and Clinical Characteristics
Overall
(N ¼ 9,290)
BARC Bleed
(n ¼ 2,246)
No BARC Bleed
(n ¼ 7,044) p Value
Demographics
Age, yrs 60.6  11.4 60.9  11.3 60.6  11.4 0.3293
Male 6,763 (72.8) 1,441 (64.2) 5,322 (75.6) <0.0001
White 8,320 (89.6) 2,036 (90.7) 6,284 (89.2) 0.0604
Private health insurance 6,083 (65.5) 1,498 (66.7) 4,585 (65.1) 0.2276
Medicare insurance 3,205 (34.5) 817 (36.4) 2,388 (33.9) 0.0374
Past medical history
Diabetes 2,350 (25.3) 513 (22.8) 1,837 (26.1) 0.0021
Hypertension 6,217 (66.9) 1,461 (65.1) 4,756 (67.5) 0.0360
Dyslipidemia 6,184 (66.6) 1,468 (65.4) 4,716 (67.0) 0.1867
Current/recent smoker 3,370 (36.3) 805 (35.8) 2,565 (36.4) 0.6444
Prior MI 1,731 (18.6) 372 (16.6) 1,359 (19.3) 0.0037
Prior PCI 1,932 (20.8) 416 (18.5) 1,516 (21.5) 0.0022
Prior CABG 855 (9.2) 185 (8.2) 670 (9.5) 0.0681
Prior stroke or TIA 483 (5.0) 113 (5.0) 370 (5.3) 0.6777
Peripheral artery disease 577 (6.2) 137 (6.1) 440 (6.3) 0.8050
Prior heart failure 497 (5.4) 105 (4.7) 392 (5.6) 0.1025
Atrial ﬁbrillation/ﬂutter 423 (4.6) 105 (4.7) 318 (4.5) 0.7514
Dialysis 89 (1.0) 20 (0.9) 69 (1.0) 0.7036
Chronic lung disease 867 (9.3) 241 (10.7) 626 (8.9) 0.0088
GI/GU bleeding within past 6 months 93 (1.0) 27 (1.2) 66 (0.9) 0.2727
In-hospital medications
Aspirin 9,137 (98.4) 2,202 (98.0) 6,935 (98.5) 0.2870
Clopidogrel 7,042 (75.8) 1,591 (70.8) 5,451 (77.4) <0.0001
Prasugrel 2,818 (30.3) 794 (35.4) 2,024 (28.7) <0.0001
Ticagrelor 237 (2.6) 59 (2.6) 178 (2.5) 0.7031
UFH 6,958 (74.9) 1,650 (73.5) 5,308 (75.4) 0.1524
LMWH 1,812 (19.5) 442 (19.7) 1,370 (19.5) 0.8288
Fondaparinux 32 (0.34) 5 (0.22) 27 (0.38) 0.3829
Bivalirudin 4,506 (48.5) 1,053 (46.9) 3,453 (49.0) 0.0828
Fibrinolytic agents 379 (7.9) 74 (6.4) 305 (8.3) 0.0682
Glycoprotein IIb/IIIa inhibitors 4,159 (44.8) 1,013 (45.1) 3,146 (44.7) 0.5759
In-hospital laboratory values
Pre-procedure CK-MB, ng/ml 36.0  74.0 35.3  90.2 36.2  68.4 0.0618
Pre-procedure troponin I, ng/ml 6.7  25.0 6.1  19.9 6.9  26.4 0.0184
Pre-procedure hemoglobin, g/dl 14.2  1.9 14.1  2.0 14.2  1.8 0.0001
Pre-procedure creatinine, mg/dl 1.1  0.7 1.1  0.6 1.1  0.7
Continued on the next page
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62(69.8  19.7 vs. 71.6  19.0; mean difference 1.8;
p ¼ 0.0002) and at 6-month follow-up (72.8  18.5 vs.
75.7  17.1; mean difference 2.9; p < 0.0001)
(Online Table 1).
After adjustment for baseline health status and
clinical factors, any BARC bleeding by 6 months was
independently associated with a decrement in health-
state utility and QOL at 6 months (Central Illustration,
Table 2). For the EQ-5D index, bleeding was associ-
ated with a change of 0.033 (95% conﬁdence
interval: 0.041 to 0.026; p < 0.0001; Cohen’s d:
0.24). For the EQ-5D VAS, any BARC bleeding was
associated with a 6-month difference of 2.5 (95%
conﬁdence interval: 3.3 to 1.8; p < 0.0001; Cohen’s
d: 0.17). As expected, more severe bleeding categorieswere associated with a greater decrement in utility
and health status as assessed by the EQ-5D index and
the EQ-5D VAS, respectively. However, even minor
(i.e., BARC type 1) bleeding was associated with sig-
niﬁcant decreases in adjusted QOL by both measures
(Central Illustration, Table 2).
DISCUSSION
Using contemporary, nationally representative data
from the TRANSLATE-ACS study, we were able to
quantify the disutility and QOL associated with post-
AMI bleeding occurring in the context of clopidogrel
and higher-potency ADP receptor inhibitor use. We
found that any BARC bleeding occurred in nearly 1 in
4 patients during the ﬁrst 6 months after AMI among
patients receiving DAPT. After adjusting for baseline
EQ-5D, as well as other patient and treatment char-
acteristics, post-discharge bleeding was associated
with signiﬁcant decrements in both health-state
utility value and QOL as measured by the EQ-5D in-
dex and EQ-5D VAS scores, respectively. Although
more severe types of bleeding (BARC types 3 or 4)
were associated with larger decrements in utility and
health status, even the most minor bleeding episodes
(BARC type 1) were associated with a measurable
decline in these metrics.
One important question that arises from these
results: are the observed decrements in QOL asso-
ciated with bleeding clinically meaningful? With the
EQ-5D index-based scores, the minimum clinically
important differences have been estimated for some
disease conditions (21–23), but empirical work has
not been performed for bleeding. Our study showed
a 0.033 decrement in utility and Cohen’s d of 0.24
associated with any BARC bleeding. In comparison,
lung cancer and limb reconstruction surgery are
both associated with reductions in the EQ-5D index-
based scores of 0.05 (22,23). Walters et al. (23)
observed that for most disease conditions, the “ef-
fect sizes” for EQ-5D index scores were in the
“small-to-moderate” range of 0.20 to 0.50 using
Cohen’s criteria. For example, all cancers are asso-
ciated with minimally important differences in the
range of 0.07 to 0.09 (22). In this context, our study
ﬁndings suggest that bleeding has a clinically
meaningful impact on patients’ QOL, comparable to
the effect sizes observed for other serious disease
conditions.
This study builds upon the ﬁndings of prior litera-
ture showing that BARC type 1 nuisance bleeding
while on clopidogrel therapy is associated with a
decrement in patient QOL (24). The present study in-
cludes a larger study population of patients treated
TABLE 1 Continued
Overall
(N ¼ 9,290)
BARC Bleed
(n ¼ 2,246)
No BARC Bleed
(n ¼ 7,044) p Value
Bleeding/transfusion
In-hospital major bleeding event 290 (3.1) 86 (3.8) 204 (2.9) 0.0268
RBC/whole blood transfusion 178 (1.9) 51 (2.3) 127 (1.8) 0.1613
In-hospital events
CABG 29 (0.3) 1 (0.0) 28 (0.4) 0.0090
Myocardial infarction 48 (0.5) 15 (0.7) 33 (0.5) 0.2512
Cardiogenic shock 110 (1.2) 27 (1.2) 83 (1.2) 0.9319
Heart failure 139 (1.5) 41 (1.8) 98 (1.4) 0.1422
CVA/stroke 8 (0.1) 1 (0.0) 7 (0.1) 0.4403
Length of stay, days 3.1  2.1 3.1  2.3 3.0  2.1 0.6715
Discharge medications
Clopidogrel 6,346 (68.3) 1,385 (61.7) 4,961 (70.4) <0.0001
Prasugrel 2,696 (29.0) 798 (35.6) 1,898 (27.0) <0.0001
Ticagrelor 197 (2.1) 47 (2.1) 150 (2.1) 0.9195
Any second-generation
ADP P2Y12 receptor inhibitor
2,893 (31.2) 845 (37.7) 2,048 (29.1) <0.0001
Aspirin 9,145 (98.8) 2,208 (98.8) 6,937 (98.9) 0.9703
Anticoagulant agents 481 (5.2) 146 (6.5) 335 (4.8) 0.0012
PCI data
PCI indication 0.3889
Immediate PCI for STEMI 4,134 (44.5) 1,023 (45.6) 3,111 (44.2)
PCI for high-risk non-STEMI
or unstable angina
4,308 (46.4) 1,044 (46.5) 3,264 (46.3)
Any DES used 6,671 (71.8) 1,648 (73.4) 5,023 (71.3) 0.0581
Procedure successful 8,605 (92.6) 2,089 (93.0) 6,516 (92.5) 0.5305
ACTION risk scores
ACTION mortality risk score (19) 30.1  7.7 30.0  7.6 30.2  7.7 0.6029
ACTION bleeding risk score (20) 25.4  6.8 25.8  6.6 25.2  6.8 <0.0001
Values are mean  SD or n (%).
ACTION ¼ Acute Coronary Treatment and Intervention Outcomes Network Registry; ADP ¼ adenosine
diphosphate; BARC ¼ Bleeding Academic Research Consortium; CABG ¼ coronary artery bypass graft surgery;
CK-MB ¼ creatine kinase MB isoenzyme; CVA ¼ cerebrovascular accident; DES ¼ drug-eluting stent; GI ¼
gastrointestinal; GU ¼ genitourinary; LMWH ¼ low-molecular-weight heparin; MI ¼ myocardial infarction; PCI ¼
percutaneous coronary intervention; RBC ¼ red blood cell; STEMI ¼ ST-segment elevation myocardial infarction;
TIA ¼ transient ischemic attack; UFH ¼ unfractionated heparin.
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63with clopidogrel, as well as higher-potency anti-
platelet agents and thus is very representative of
contemporary clinical practice patterns in the United
States. We also have quantiﬁed the decrement in
utility and QOL of all types of BARC bleeding in
addition to BARC type 1 nuisance bleeding. Of note,
the decrement in QOL scores with BARC type 1
bleeding was almost identical in magnitude to that
observed in our prior study from the TRIUMPH
(Translational Research Investigating Underlying
Disparities in Acute Myocardial Infarction Patients’
Health Status) registry (25).
Bleeding on DAPT occurs commonly. In the present
study, nearly 1 in 4 patients had some form of
bleeding on DAPT during a 6-month follow-up period.
Therefore, this study has important implications for
clinical practice, as well as for future clinical trials. It
identiﬁes that post-AMI bleeding occurring on DAPT
is an outcome of direct clinical consequence to pa-
tients, irrespective of the severity of the bleeding
event. Even the most trivial form of bleeding—the
BARC type 1 “nuisance” bleeding events—were asso-
ciated with signiﬁcantly reduced utility and QOL. The
more severe bleeding events were associated with
even greater reductions in utility and QOL. In a prior
study from TRANSLATE-ACS, we observed that
bleeding is underreported to treating clinicians (12).
As antiplatelet and anticoagulant regimens continue
to evolve and are applied in routine clinical practice,
our study establishes the critical need for more pro-
active assessment of bleeding, including minor
bleeding events, during treatment. When DAPT is
clearly necessary for prevention of stent thrombosis
and other adverse cardiovascular events after AMI or
PCI, patients should be counseled on what to expect
to prevent interruptions in treatment. The very high
rate of bleeding seen in the ﬁrst 6 months on DAPT
also challenges clinicians to reassess the feasibility of
shorter DAPT durations especially in light of newer
stent platforms and other innovations (26–31).
Quantifying the utility decrement associated with
the BARC bleeding deﬁnition has important implica-
tions for the conduct of clinical trials. Until recently,
patient-reported, less severe forms of bleeding have
not been collected or adjudicated in trials. By quan-
tifying the utility decrement associated with the
spectrum of bleeding severity, this study places BARC
bleeding in context for future clinical trials involving
QOL and/or other patient-reported outcomes. These
patient-reported outcomes may be especially impor-
tant for future trials evaluating antiplatelet regimen
durations or novel agents associated with a risk of
bleeding complications.STUDY LIMITATIONS. First, in the TRANSLATE-ACS
study, BARC type 1 bleeding was based only on pa-
tient self-reporting and may have been subject to
recall bias. However, this self-reported method of
evaluating BARC type 1 bleeding was speciﬁcally
intended when the BARC deﬁnitions were developed.
Second, despite rigorous multivariable adjustment,
there remains the possibility of unmeasured con-
founding in this observational study. Third, the pos-
sibility of selection bias due to the exclusion of
patients with missing data regarding 6-month health
status (n ¼ 1,928; 16.5%) may limit the precision and
generalizability of our estimates. Finally, despite
observing a statistically signiﬁcant association be-
tween bleeding and a decrement in QOL, the causal
nature of this association cannot be inferred given
our observational study design.
CENTRAL ILLUSTRATION QOL and Disutility Associated With Bleeding After AMI
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BARC 1 Bleeding Vs. None BARC 1 Bleeding Vs. None
BARC 2-4 Bleeding Vs. None BARC 2-4 Bleeding Vs. None
BARC 3-4 Bleeding Vs. None BARC 3-4 Bleeding Vs. None
 Adjusted Differences in EQ-5D Utility Index                                                   Adjusted Differences in EQ-5D VAS Score
Amin, A.P. et al. J Am Coll Cardiol. 2016; 67(1):59–65.
The stepwise relationship of quality of life (QOL) and utility decrement associated with increasing severity of bleeding. The EQ-5D Utility Index is based on
U.S. weights on a 0.11 to 1.00 scale (where 1.00 is best). EQ-5D VAS is on a 1 to 100 scale (where 100 is best). BARC ¼ Bleeding Academic Research
Consortium; EQ-5D ¼ Euro QOL–5 Dimension; VAS ¼ visual analog scale. AMI ¼ acute myocardial infarction.
TABLE 2 QOL and U
Model
EQ-5D Utility Index*
Any BARC bleeding v
BARC 1 bleeding vs.
BARC 2–4 bleeding v
BARC 3–4 bleeding v
EQ-5D VAS†
Any BARC bleeding v
BARC 1 bleeding vs.
BARC 2–4 bleeding v
BARC 3–4 bleeding v
*Based on U.S. weights; 
CI ¼ conﬁdence interval
other abbreviations as in T
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64CONCLUSIONS
We found a very high incidence of BARC bleeding
during the ﬁrst 6 months after AMI among patients
discharged on DAPT. Bleeding was associated with
worse health-state utility and patient-reported QOL,
an association that persisted for even minor BARC
type 1 bleeding events. These ﬁndings reinforce the
need to proactively assess and address patient-
reported bleeding concerns while on DAPT. Bytility Decrement Associated With Increasing Severity of Bleeding
Effect Estimate 95% CI p Value Cohen’s d
s. none 0.0334 0.0407 to 0.0261 <0.0001 0.24
none 0.0257 0.0365 to 0.0148 <0.0001
s. none 0.0381 0.047 to 0.0293 <0.0001
s. none 0.0445 0.073 to 0.016 0.0022
s. none 2.5023 3.2525 to 1.752 <0.0001 0.17
none 2.0385 3.1504 to 0.9266 0.0003
s. none 2.7898 3.6964 to 1.8831 <0.0001
s. none 7.0974 10.037 to 4.1575 <0.0001
0.11 to 1.00 scale (where 1.00 is best). †1 to 100 scale (where 100 is best).
; EQ-5D ¼ Euro QOL—5 Dimension; QOL ¼ quality of life; VAS ¼ visual analog scale;
able 1.quantifying the utility decrement associated with the
standardized BARC bleeding deﬁnition, this study
facilitates application and interpretation of bleeding
endpoints in future trials of antithrombotic treatment
regimens.
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COMPETENCY IN MEDICAL KNOWLEDGE: Pro-
longed DAPT is recommended to prevent recurrent
ischemic events after AMI and PCI but is associated
with increased bleeding. Patients who develop
bleeding during DAPT exhibit worse health status and
quality of life after 6 months proportionate to the
severity of bleeding.
TRANSLATIONAL OUTLOOK: Further investiga-
tion is needed to elucidate the causes of the adverse
long-term effects of bleeding on DAPT and to develop
strategies that ameliorate risk.
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